New Micropeptins with Anti-Neuroinflammatory Activity Isolated from a Cyanobacterial Bloom (June 4, 2021) Abstract Metabolite mining of environmentally collected aquatic and marine microbiomes offers a platform for the discovery of new therapeutic lead molecules. Combining a prefractionated chromatography library with liquid chromatography tandem mass spectrometry (LC-MS/MS)-based molecular networking and biological assays, we isolated and characterized two new micropeptins (1 and
Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more than $500 million in upfront and contingent milestone payments Seres Therapeutics to conduct a conference call at 8:30 a.m. ET CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Seres Therapeutics, Inc.
